echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > The first long-acting preventive new crown antibody combination drug Phase 3 has a positive clinical effect and significantly reduces the incidence of symptoms

    The first long-acting preventive new crown antibody combination drug Phase 3 has a positive clinical effect and significantly reduces the incidence of symptoms

    • Last Update: 2021-09-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    August 21, 2021, Shanghai, China - AstraZeneca's AZD7442 PROVENT Phase III pre-exposure prevention clinical trial has achieved positive results, significantly reducing the incidence of symptomatic new coronary pneumonia ( COVID-19 ) and reaching the primary endpoint


    Prevent new crown pneumonia COVID-19

    As a combination of two long-acting antibodies (LAAB), AZD7442 can reduce the incidence of symptomatic new coronary pneumonia by 77% (95% confidence interval (CI): 46, 90) compared to the control group


    Infect

    Among the subjects treated with AZD7442, there were no severe cases or deaths caused by infection with the new coronavirus


    AZD7442 is the first optimized antibody combination drug (non-vaccine) that has been proven to be capable of long-term prevention of new coronary pneumonia in clinical trials


    A total of 5197 subjects were enrolled in this clinical trial, of which the AZD7442 test group and the control group were randomly allocated according to the number of cases 2:1.


    immunity

    Preliminary data analysis showed that subjects tolerated AZD7442 well, and the incidence of adverse events was the same in the control group and the AZD7442 test group


    Myron J.


    Mene Pangalos , executive vice president of AstraZeneca and head of biopharmaceutical research and development, said: "We hope to find other ways for people who have not yet been fully protected by the new crown vaccine


    Mene Pangalos

    AZD7442 is optimized by AstraZeneca’s proprietary YTE half-life extension technology.


    The results of in vitro experiments conducted by researchers at Oxford University in the United Kingdom and Columbia University in the United States showed that AZD7442 can neutralize the newly discovered SARS-CoV-2 mutant virus, including the delta mutant strain


    AstraZeneca will submit these preventive studies (PROVENT and STORM CHASER) data to regulatory agencies, seeking emergency use authorization or conditional approval


    About PROVENT

    About PROVENT

    PROVENT is a randomized, double-blind, placebo-controlled, multi-center phase III clinical trial designed to evaluate the safety and effectiveness of a single dose of AZD7442 300 mg in the prevention of new coronaviruses


    The primary efficacy endpoint of PROVENT was the first positive case of SARS-CoV-2 RT-PCR within 183 days after receiving the injection


    All subjects are adults 18 years of age and older, and are high-risk groups that are expected to benefit from the preventive mechanism of the long-acting antibody combination drug: insufficient immune response (weak vaccine response or vaccine intolerance) or more likely to be infected with SARS- The CoV-2 virus may be exposed to the high-risk environment of SARS-CoV-2 virus infection


    Approximately 43% of the subjects are people 60 years and older, and more than 75% are accompanied by underlying diseases and other diseases (including immunosuppressive diseases or taking immunosuppressive drugs, diabetes , severe obesity or heart disease, chronic obstructive pulmonary disease, chronic Kidney and liver diseases), once infected with the new coronavirus, the risk of developing severe illness is higher


    diabetes

    About AZD7442

    About AZD7442

    AZD7442 is a combination of two long-acting antibodies tixagevimab (AZD8895) and cilgavimab (AZD1061), extracted from B cells of convalescent patients infected with SARS-CoV-2


    A comprehensive clinical trial involving more than 9,000 people is underway to evaluate the role of AZD7442 in the prevention and treatment of new coronaviruses, including TACKLE COVID-1913, a phase III clinical trial conducted in an outpatient clinic, and a combination of outpatient treatment and inpatient treatment Research
    .
    In addition, the evaluation of the different modes of administration of AZD7442 intramuscularly and intravenously is also underway
    .



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.